Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ARS-1

Other · developed by ARS Pharmaceuticals

Phase 2 Most advanced trial (none active)

SPRY Developer

3 Registered trials

What is ARS-1?

ARS-1 is an investigational drug studied in Upper Respiratory Tract Infection, Asthma, Urticaria.

At a glance

Drug type: Other
Therapy area: Dermatology, Immunology, Respiratory
Developer: ARS Pharmaceuticals, Inc. (SPRY)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05496465	Phase 2	Urticaria	Completed	SPRY
NCT05363670	Phase 2	Asthma	Completed	SPRY
NCT04930900	Phase 1	Upper Respiratory Tract Infection	Completed	SPRY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

AsthmaUpper Respiratory Tract InfectionUrticaria

Sources

ClinicalTrials.gov NCT05496465

Updated Oct 3, 2026. Something wrong or missing? Report it on the SPRY page.

Follow SPRY, the company behind ARS-1

See SPRY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SPRY catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z